Telisotuzumab vedotin is a monoclonal antibody developed by AbbVie for non-small cell lung cancer.[1][2][3][4][5]
^Camidge, D. Ross; Barlesi, Fabrice; Goldman, Jonathan W.; Morgensztern, Daniel; Heist, Rebecca; Vokes, Everett; Spira, Alex; Angevin, Eric; Su, Wu-Chou; Hong, David S.; Strickler, John H.; Motwani, Monica; Dunbar, Martin; Parikh, Apurvasena; Noon, Elysa; Blot, Vincent; Wu, Jun; Kelly, Karen (10 February 2023). "Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer". Journal of Clinical Oncology. 41 (5): 1105–1115. doi:10.1200/JCO.22.00739. ISSN 0732-183X. PMC 9928626.
^Fujiwara, Yutaka; Kenmotsu, Hirotsugu; Yamamoto, Noboru; Shimizu, Toshio; Yonemori, Kan; Ocampo, Christopher; Parikh, Apurvasena; Okubo, Sumiko; Fukasawa, Kazuteru; Murakami, Haruyasu (April 2021). "Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors". Cancer Medicine. 10 (7): 2350–2358. doi:10.1002/cam4.3815. ISSN 2045-7634. PMC 7982615.
^Camidge, D. Ross; Barlesi, Fabrice; Goldman, Jonathan W.; Morgensztern, Daniel; Heist, Rebecca; Vokes, Everett; Angevin, Eric; Hong, David S.; Rybkin, Igor I.; Barve, Minal; Bauer, Todd M.; Delmonte, Angelo; Dunbar, Martin; Motwani, Monica; Parikh, Apurvasena; Noon, Elysa; Wu, Jun; Blot, Vincent; Kelly, Karen (January 2022). "A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC". JTO Clinical and Research Reports. 3 (1): 100262. doi:10.1016/j.jtocrr.2021.100262. PMC 8717236.
^Waqar, Saiama N.; Redman, Mary W.; Arnold, Susanne M.; Hirsch, Fred R.; Mack, Philip C.; Schwartz, Lawrence H.; Gandara, David R.; Stinchcombe, Thomas E.; Leighl, Natasha B.; Ramalingam, Suresh S.; Tanna, Saloni H.; Raddin, Ryan S.; Minichiello, Katherine; Bradley, Jeffrey D.; Kelly, Karen; Herbst, Roy S.; Papadimitrakopoulou, Vassiliki A. (1 May 2021). "A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)". Clinical Lung Cancer. 22 (3): 170–177. doi:10.1016/j.cllc.2020.09.013. ISSN 1525-7304. PMC 8044254.
^Strickler, John H.; Weekes, Colin D.; Nemunaitis, John; Ramanathan, Ramesh K.; Heist, Rebecca S.; Morgensztern, Daniel; Angevin, Eric; Bauer, Todd M.; Yue, Huibin; Motwani, Monica; Parikh, Apurvasena; Reilly, Edward B.; Afar, Daniel; Naumovski, Louie; Kelly, Karen (20 November 2018). "First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors". Journal of Clinical Oncology. 36 (33): 3298–3306. doi:10.1200/jco.2018.78.7697.
and 25 Related for: Telisotuzumab vedotin information
Telisotuzumabvedotin is a monoclonal antibody developed by AbbVie for non-small cell lung cancer. Camidge, D. Ross; Barlesi, Fabrice; Goldman, Jonathan...
Global Information